UNSPSC 51294419: Etoperidone hydrochloride

This classification denotes an antiemetic agent with the molecular formula C19H28ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2FSU2FR80J, chemically known as 1,2,4-triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-4,5-diethyl-2,4-dihydro- but more generally known as etoperidone hydrochloride, which bears US NIH Compound Identifier 40589. Most nations, for tariff and trade purposes, schedule etoperidone hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, ETOPERIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etoperidone hydrochloride bears US NLM identifiers UMLS ID C1880588 and NCI Concept Code C63783. SMILES: CCC1NN(C(=O)N1CC)CCCN2CCN(CC2)C3CCCC(C3)CL.CL.

UNSPSC 51294419 Etoperidone hydrochloride is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local solicitations tagged with this code show little alignment with the specific drug name itself. The opportunities identified instead span naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals through cooperative purchasing — suggesting either misclassification of opportunities at the posting stage or use of this code as a catchall for pharmaceutical-procurement activity that does not map to a single active ingredient. State and local issuing bodies pursuing pharmaceutical contracts include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The actual work being solicited centers on supply chain fulfillment of generic drugs, over-the-counter products, and emergency-response medications (naloxone) through authorized wholesalers, with compliance requirements including Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and FDA authorization.

Recent activity shows solicitations posted across Florida, Texas, Minnesota, and Oregon. Seminole County posted an Invitation for Bid (IFB 60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries due by July 26, 2023, and E-Verify and drug-free workplace certification required. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) in April 2026 to solicit vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award value or timeline specified as of the information-gathering phase. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, released a Request for Proposal (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with responses due March 26, 2026, and contract effectiveness July 1, 2026; vendors must maintain commercial general liability insurance of $5,000,000 and comply with a 3 percent administrative fee structure on all contract purchases. The code shows sparse recent activity and the opportunities present do not cleanly track to etoperidone hydrochloride as a distinct procurement driver.